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Non-small  cell  lung  cancer  (NSCLC)  therapy  has  entered  a rapidly  advancing  era of precision  medicine
with  an  ever  increasing  number  of drugs  directed  against  a variety  of  speciﬁc  tumor  targets.  Amongst
these  new  agents,  tyrosine  kinase  inhibitors  (TKIs)  and  monoclonal  antibodies  (mAbs)  are  most  fre-
quently  used.  However,  as  only  a sensitive  subgroup  of  patients  beneﬁts  from  targeting  drugs,  predictive
biomarkers  are  needed.  Positron  emission  tomography  (PET)  may  offer  such  a biomarker  for  predictingSCLC
ET
KI-PET
mmuno-PET
therapy  efﬁcacy.  Some  of  the  TKIs  and  mAbs  that  are  in  clinical  use can  be radioactively  labeled  and  used
as  tracers.  PET  can  visualize  and  quantify  tumor  speciﬁc  uptake  of  radiolabeled  targeting  drugs,  allowing
for characterization  of  their  pharmacokinetic  behavior.  In this  review,  the  clinical  potential  of PET using
radiolabeled  TKIs  (TKI-PET)  and  mAbs  (immuno-PET)  in  NSCLC  is discussed,  and  an  overview  is provided
of  the  most  relevant  preclinical  and  clinical  studies.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Non-small cell lung cancer (NSCLC) causes the highest cancer-
elated mortality worldwide [1]. Until a decade ago, the number of
ystemic treatment options was limited. However, with advance-
ents in molecular genotyping of NSCLC tumors, ever more
ctionable molecular targets are being identiﬁed. Highly speciﬁc
rugs directed against these targets are rapidly being developed
nd approved (see Table 1). Targeting drugs like tyrosine kinase
nhibitors (TKIs) and monoclonal antibodies (mAbs) have demon-
trated to improve clinical outcome in target-positive tumors. For
xample, epidermal growth factor receptor (EGFR) TKIs achieve
esponse rates up to 70% in patients with activating EGFR muta-
ions [2]. Furthermore, mAbs directed against immune checkpoint
argets such as PD1, PDL1 or CTLA4 may  achieve very long dura-
ions of response, even reaching several years in a limited numberPlease cite this article in press as: I. Bahce, et al., Personalizing NSCLC t
Lung Cancer (2016), http://dx.doi.org/10.1016/j.lungcan.2016.05.025
f patients [3]. However, in patients with target-negative tumors,
ost targeting drugs perform worse than cytotoxic agents. In addi-
ion, the costs of these new targeting drugs are much higher as
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compared to classical cytotoxic agents. For example, in 2015 the
quality adjusted life year cost of nivolumab was estimated at
134.000 D by the Netherlands National Health Care Institute. These
facts highlight the necessity for limiting the use of these drugs to
sensitive patients, i.e. personalizing therapy.
A promising new approach for personalizing therapy is the
use of positron emission tomography (PET) and radioactively
labeled drugs. Classically, pharmacokinetic (PK) analysis of newly
developed drugs is performed by serial assessment of drug and
metabolites concentrations in plasma and sometimes in urine or
stool samples after administrating the drug orally or intravenously.
Using PET, radiolabeled drugs can be used as PET tracers that allow
for PK studies [4]. Compared to preclinical and clinical PK studies,
PET provides a faster and more cost-effective approach, moreover,
it provides additional information e.g. on drug modeling and on
the drug tissue distribution, particularly on drug uptake in tumors.
These PK insights are now being used to study the potential of PET
as a predictive imaging biomarker.
This review will mention some of the general principles of
PET and then focus on the current research and potential clinicalherapy by characterizing tumors using TKI-PET and immuno-PET,
implications of PET using radiolabeled mAbs (immuno-PET) and
TKIs (TKI-PET) in personalizing NSCLC therapy. Literature searches
were performed in PubMed and references from relevant articles
using the search terms “NSCLC”, “immuno”, “TKI”, “radionuclide
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Fig. 1. The basic mechanism of action of PET is shown. A patient with a tumor,
in  which a radiolabeled mAb is bound to a tumor cell, is depicted. The radionuclide
emits a positron that annihilates with a nearby electron, hereby producing 2 gamma
ray photons, each with an energy of 511 keV. The oppositely directed photons are
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too early causes low signal-to-noise ratios, and scanning too lateetected by the PET scanner. Calculating each of the synchronously detected pairs
f  photons allows for a 3-dimensional reconstruction of the tracer distribution.
maging”, “PET”, and their synonyms (see Supplementary Table 1
nd Supplementary Table 2). Only publications in English, up to
ebruary 2016, were included.
. General principles of PET, possibilities and limitations
PET is an imaging technique that utilizes gamma  rays, emitted
y positron emitting tracers, to produce 3-dimensional images (see
ig. 1). Using PET, the PK behavior of tracers can be imaged in vivo.
or example, the most often used PET tracer in NSCLC is ﬂuorine-
8 labeled ﬂuorodeoxyglucose ([18F]FDG or FDG), a glucose analog
hat accumulates in cells with high glucose metabolism. FDG was
he ﬁrst widely used PET tracer to improve disease staging, i.e. by
etter identifying lymph node metastases and distant metastases.
his improvement in disease staging led to a decrease in futile
horacotomies, e.g. a 20% decrease in the absolute number of thora-
otomies was seen in the Amsterdam region [5,6]. Besides staging,
DG PET was also used to assess metabolic response. For example,
etabolic changes after chemoradiotherapy could predict residual
ital tumor cells in NSCLC tumors [7]. However, FDG is only spe-
iﬁc for glucose metabolism. To identify the previously mentioned
ctionable molecular targets, speciﬁc PET tracers are needed.
A great advantage of PET is that targeting drugs themselves can
e used as PET tracers, provided that they can be labeled with a
ositron emitting radionuclide. The PK behavior of these radiola-
eled drugs can then be studied. These PK insights are both useful
or developing new drugs, as well as for clinical use, as the binding
f radiolabeled drugs to tumors possibly predicts for tumor sen-
itivity to therapy. In addition, tumor sensitivity to therapy can
ary between and within tumor lesions. Heterogeneity of target
xpression is typically determined by (molecular) pathology, the
old standard for diagnosis, either obtained by tumor biopsies or
rom circulating tumor products in blood, such as proteins, miRNA
r DNA [8]. PET using radiolabeled drugs could offer additional ben-
ﬁts to pathology, namely in overcoming some of the limitations
ssociated with pathology. For example, obtaining high yields of
epresentative tumor samples to establish the correct diagnosis is
ot always possible due to difﬁculties reaching the tumor [9]. A
imitation associated with blood sampling markers is the fact that
he obtained data cannot be related to a speciﬁc lesion. Here, PETPlease cite this article in press as: I. Bahce, et al., Personalizing NSCLC t
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ay help by providing (whole body) imaging that takes multiple
umor lesions as well as normal tissues into account. This bears an
normous potential for tailoring therapy to ﬁt the patient’s individ- PRESS
 xxx (2016) xxx–xxx
ual needs. In addition, this technique is in vivo, non-invasive and
not prone to sampling errors.
However, there are limitations to PET imaging. Ideally, drugs
are labeled with radionuclides by way  of substitution. As this will
not alter the parent molecule’s conﬁguration, the PK of the parent
drug’s unlabeled and labeled form remains identical. When substi-
tution is not possible, the radionuclide will be attached to the parent
drug. The molecular structure of the labeled form is then altered,
whereby the PK of the tracer may  not be fully representative of the
parent drug anymore. Furthermore, large interpatient differences
in terms of tracer metabolism can cause alterations in the signal-
to-noise ratio and hamper a clear interpretation of the data. Other
limitations are associated with the choice of the scanning protocol
(see Fig. 2). A dynamic protocol allows for accurate quantiﬁcation
of tracer uptake, however, is constrained to a single ﬁxed ﬁeld of
view and does not allow whole body techniques. However, if the
intention of the protocol is to scan the whole of the body, a static
protocol will be used and quantiﬁcation of uptake will be less accu-
rate as compared to the dynamic scanning protocols. There may be
infrastructural limitations such as the absence of a tracer produc-
tion capacity. e.g. a cyclotron. Typically any very short-lived tracer
like carbon-11 labeled TKI has to be produced immediately prior to
injection and is not suited for shipping to remote centers.
3. Immuno-PET
The current antibody therapies are shown in Table 1 (see also
Fig. 3). Radiolabeled mAbs that have been investigated in immuno-
PET studies are shown in Table 2.
Monoclonal antibodies are large molecules of approximately
150 kD that are relatively easy to radiolabel in an inert way, i.e. that
neither binding nor PK characteristic of the drug becomes altered
[38]. As large molecules, mAbs are characterized by slow tissue
penetration. Therefore, to image their PK behavior, mAbs need to
be labeled with long-lived radionuclides such as zirconium-89 (see
Table 3). Usually, radiolabeled mAbs do not allow for dynamic scan-
ning because of their slow PK proﬁle (see Fig. 2). Rather, static whole
body scanning protocols are performed. As radiolabeled mAbs fully
bind to their targets only after a few days post injection (p.i.), static
images using simpliﬁed uptake parameters, such as standardized
uptake value (SUV), tumor-to-blood (TBR), and tumor-to-reference
tissue ratios, are best suited.
For optimizing the tumor uptake signal against the background
noise, the choice of radionuclide is a key variable. After recep-
tor binding, mAbs can become internalized by the target cells.
Some long-lived radionuclides, such as bromine-76 and iodine-124
are then rapidly degraded and cleared from these cells. How-
ever, copper-64, yttrium-86 and zirconium-89 become captured
intracellularly, causing a higher signal-to-noise ratio [38]. Also,
some mAbs can show a sink effect, i.e. a large number of extra-
tumoral receptor molecules has to be saturated before tumor
receptor molecules can be imaged. In such cases, simultaneous
injection of cold doses of mAbs with radiolabeled mAbs is needed
to improve image quality [22,23]. However, co-injection of cold
mAbs also affects the quantiﬁcation of tumor uptake as tumor tar-
get molecules become occupied with cold mAbs, thus decreasing
accuracy of quantiﬁcation. Imaging quality can also be determined
by the timing between tracer injection and scanning, as scanningherapy by characterizing tumors using TKI-PET and immuno-PET,
suffers from too much decay leading to poor statistics for image
reconstruction and quantiﬁcation. Typically, patients are scanned
several days after injection of radiolabeled mAbs.
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Fig. 2. Main differences between static and dynamic scanning procedures are shown schematically. Using a dynamic protocol, PET continuously scans a ﬁxed single Field of
View  (FoV) of approximately 18 cm that contains the volume of interest (e.g. tumor = blue octagon) and an arterial blood pool (e.g. the left ventricle, aorta or large arteries = red
cone  and red lines). The post tracer injection time (radio)activity curves (TACs) of the tumor and arterial blood pool are plotted (typically for several minutes to several hours).
An  accurate uptake measure can be calculated using these TACs. This protocol is typically used for tracers with a rapid PK proﬁle. In static scanning, a single FoV is scanned for
a  relatively short period of time (usually several minutes), allowing for multiple FoVs to be scanned (e.g. when multiple tumor lesions are present = blue octagons). Typically,
static  scans are performed using tracers that reach a steady state in their tumor TAC (or tumor-to-blood ratio) or using tracers with a slow PK (e.g. radiolabeled mAbs). The
latter  scenario allows for multiple scans after a single injection, as depicted above. The plotted (radio)activity concentration in the tumor lesions (blue octagons) is the highest
at  day 5 post injection, while the tumor-to-blood ratio is the highest on day 7, as the blood pool activity (red dots) continuously decreases.
Fig. 3. A simpliﬁed overview of the targets and mechanisms of action of the targeting drugs used in NSCLC is depicted.
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Table  1
NSCLC targeted therapies and FDA-approval status.
Drug class Generic name Trade name Target T½ Cancer indication FDA approval status
(date)
TKI Erlotinib Tarceva EGFR 36 h NSCLC with activating EGFR
mutationsb, 1st line
Approved May  2013
TKI  Afatinib Gilotrif (Giotrif)a EGFR/ERBB2 37 h NSCLC with activating EGFR
mutationsb, 1st line
Approved Jul 2013
TKI  Geﬁtinib Iressa EGFR 48 h NSCLC with activating EGFR
mutationsb, 1st line
Approved Jul 2015
TKI  Osimertinib Tagrisso EGFR 48 h NSCLC with T790 M mutation-positive
EGFR, in 2nd line after PD on treatment
with an FDA-approved, EGFR TKI.
Approved Nov 2015
TKI  Rociletinib EGFR 2–4 h NSCLC with T790 M mutation-positive
EGFR, in 2nd line after PD on treatment
with an FDA-approved, EGFR TKI.
Breakthrough Therapy
Designation May 2014
TKI  BI1482694
(HM61713)
EGFR NSCLC with T790 M mutation-positive
EGFR, in 2nd line after PD on treatment
with an FDA-approved, EGFR TKI.
Breakthrough Therapy
Designation December
2015
TKI  Crizotinib Xalkori ALK 42 h NSCLC with ALK activation Approved Nov 2013
TKI  Ceritinib Zykadia ALK 41 h NSCLC with ALK activation, 2nd line
when not able to be treated with
crizotinib or PD while on crizotinib
Approved Apr 2014
TKI  Alectinib Alecensa ALK 20 h NSCLC with ALK activation, 2nd line
when not able to be treated with
crizotinib or PD while on crizotinib
Approved Dec 2015
TKI  Brigatinib ALK NSCLC with ALK activation, 2nd line
when not able to be treated with
crizotinib or PD while on crizotinib
Breakthrough Therapy
Designation Oct 2014
TKI  Dabrafenib Taﬁnlar BRAF 8 h NSCLC with BRAF V600E mutations, in
2nd line after platinum containing
regimen.
Breakthrough Therapy
Designation Jan 2014
mAb  Necitumumab Portrazza EGFR 14 days NSCLC squamous, in 1st line combined
with doublet
Approved Nov 2015
mAb  Bevacizumab Avastin VEGF 20 days NSCLC, in 1st line combined with
carboplatin and paclitaxel
Approved Oct  2006
mAb  Ramucirumab Cyramza VEGFR 15 days NSCLC, in 2nd line with docetaxel after
platinum containing regimen.
Approved Dec 2014
mAb  Pembrolizumab Keytruda PD1 26 days NSCLC (non-EGFR, non-ALK)c with
PD-L1 in 2nd line after platinum
containing regimen.
Approved Oct  2015
mAb  Nivolumab Opdivo PD1 27 days NSCLC (non-EGFR, non-ALK)c in second
line after platinum containing regimen.
Approved Oct  2015
mAb  Atezolizumab PD-L1 21 days NSCLC (non-EGFR, non-ALK)c with
PD-L1 in 2nd line after platinum
containing regimen.
Breakthrough Therapy
Designation Feb 2015
FDA approved drugs and drugs granted Breakthrough Therapy Designation status as of February 2016 are listed.
Abbreviations: ALK = anaplastic lymphoma kinase; EGFR = epidermal growth factor receptor; FDA = U.S. Food and Drug Administration; NSCLC = non-small cell lung can-
cer;  PD = progressive disease; PD1 = programmed death-1; PD-L1 = programmed death ligand-1; T½ = mean biological elimination half life according to FDA prescribing
information; VEGF = vascular endothelial growth factor; VEGFR = VEGF receptor.
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b Patients harboring an EGFR exon 19 deletion or an exon 21 (L858R) substitution
c Patients with EGFR or ALK genomic tumor aberrations should have PD on FDA-
.1. EGFR
Panitumumab and cetuximab are IgG2 and IgG1 antibodies
irected against EGFR, respectively. In most xenograft PET stud-
es, these radiolabeled anti-EGFR drugs showed increased uptake in
GFR-expressing tumors [11–14,20]. Tracer uptake correlated with
GFR expression levels in some studies, but not in all [10,21,39].
he authors mentioned that decreased vessel density and vascular
ermeability may  have caused this discrepancy. Other causes may
ave been variations in tumor size, injected dose, tumor interstitial
ressure, and ex vivo assessment of EGFR expression. Uptake of both
adiolabeled panitumumab and cetuximab could be blocked by
dding nonlabeled drugs, indicating that there was speciﬁc binding.
o our knowledge, 2 clinical immuno-PET studies were published,
sing an anti-EGFR mAb. Van Loon et al. performed a phase 1 study
sing [89Zr]cetuximab, co-injected with cold cetuximab, in patientsPlease cite this article in press as: I. Bahce, et al., Personalizing NSCLC t
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ith NSCLC (N = 6) and head and neck cancer (N = 3) [22]. They
ound no toxicity associated with this tracer at a dose of 120MBq.
umor tracer uptake could be visualized as indicated by maximumtion as detected by an FDA-approved test.
ved therapy for these aberrations.
TBR, which ranged from 0.9 to 14.8. These values were not corre-
lated with EGFR expression in tumor samples. This study did not
investigate the predictive value of tracer uptake. The other clin-
ical study was  performed by Menke et al. in 10 KRAS wild type
colorectal cancer patients using a co-injection of [89Zr]cetuximab
and cold cetuximab [23]. Patients underwent 6 serial PET scans
from 1 h to 10 days post injection. Six out of 10 patients showed
increased uptake, of whom 4 experienced beneﬁt of the cetuximab
therapy, while 3 out of 4 patients without increased uptake had
progressive disease. These ﬁndings indicates that not only tumor
[89Zr]cetuximab binding can be visualized in patients, high tracer
uptake may  be associated with an increased response to cetuximab
therapy.
3.2. VEGF/VEGFRherapy by characterizing tumors using TKI-PET and immuno-PET,
Bevacizumab and ramucirumab are IgG1 antibodies directed
against VEGF-A and VEGFR2, respectively. All preclinical studies
showed an increased tumor uptake of radiolabeled bevacizumab
Please cite this article in press as: I. Bahce, et al., Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET,
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Table  2
Immuno-PET trials.
Drug
target
Year
Ref
Tracer (injected
dose)
Design—scanned
population
Xenograft cell line Scanning protocol
–  Timinga
– uptake parameter
Resultsb
EGFR 2009
[10]
64Cu-DOTA-
panitumumab
(7–8 MBq)
athymic nude mice
with subcutaneous
xenografts
SQB20
SAS
UM-SCC-22B
4 to 48 h
%ID/g
Tracer uptake was lowest in the cell line with
highest EGFR expression. However, this cell
line demonstrated the lowest vessel density
and vascular permeability, which may  have
caused this effect.
EGFR  2010
[11]
86Y-CHX-A”-DTPA-
panitumumab
(1.8–2.0 MBq)
athymic nude mice
with subcutaneous
xenografts
LS-174T
PC-3
A431
0.5 to 3 days
%ID/cc
The highest tracer uptake was seen in the
highest EGFR-expressing cell line, and uptake
increased from day 1 through 3. Adding cold
panitumumab uptake blocked tracer uptake.
EGFR  2011
[12]
86Y- CHX-A”-DTPA-
panitumumab
86Y- CHX-A”-DTPA-
cetuximab
(1.7–1.9 MBq)
athymic nude mice
with subcutaneous
xenografts
NCI-H226
NCI-H2052
MSTO-211H
0.5 to 3 days
%ID/cc
Both tracers showed comparable high tumor
uptake in EGFR-expressing xenografts. Uptake
was  blocked by cold mAb. Blood clearance of
86Y-cetuximab was  faster than
86Y-panitumumab. Tumor-to-liver ratio was
higher in 86Y-panitumumab than
86Y-cetuximab.
EGFR 2012
[13]
[89Zr]panitumumab
(1.7–1.9 MBq)
athymic nude mice
with subcutaneous,
intraperitoneal and
pulmonary xenografts
LS-174T
A431
A375
1 to 7 days
%ID/g
Tracer uptake was higher in EGFR expressing
cell lines. Uptake was blocked by adding cold
panitumumab. The highest uptake was  seen in
peritoneal tumors, then thoracic and then
subcutaneous tumors of EGFR expressing cell
lines.
EGFR  2013
[14]
[89Zr]panitumumab
(10.18 ± 1.24 MBq)
athymic nude mice
with subcutaneous
xenografts
BT-474,
MDA-MB-231
MDA-MB-468
1 to 6 days
%ID/g
High tracer uptake was seen in high EGFR
expressing cell lines, uptake was highly
correlated with EGFR expression levels.
EGFR  2005
[15]
[89Zr]cetuximab
(0.32–0.5 MBq)
athymic nude mice
with subcutaneous
xenografts
A431 1 to 6 days
%ID/g
High tracer uptake was seen in the
EGFR-expressing tumor.
EGFR  2007
[16]
64Cu-DOTA-
cetuximab
(5–10 MBq)
athymic nude mice
with subcutaneous
(MDA-MB-435 in
mammary fat pad)
xenografts
U87MG
PC-3
CT-26
HCT-8
HCT-116
SW620
MDA-MB-435
1 to 48 h
%ID/g
Linear correlation between tracer uptake and
EGFR expression in tumors. Uptake reaching a
plateau after 24 h.
EGFR  2008
[17]
64Cu-DOTA-
cetuximab
(5.6 and 7.8 MBq)
athymic nude mice
with subcutaneous
(MDA-MB-435 in
mammary fat pad)
xenografts
A431
MDA-MB-435
4 to 46 h
SUV
High tracer uptake was only seen in the high
EGFR expressing cell line. Tracer uptake was
blocked by adding cold cetuximab.
EGFR 2008
[18]
64Cu-DOTA-
cetuximab
(7.4 MBq)
athymic nude mice
with subcutaneous
xenografts
CaSki At 24 h p.i.
SUV
High tracer uptake was seen in the high
EGFR-expressing tumor.
EGFR  2009
[19]
[89Zr]cetuximab
(3.75 ± 0.14 MBq)
athymic nude mice
with subcutaneous
xenografts
A-431
T-47D
U-373
HT-29
1 to 96 h
%ID/cc
Tracer uptake was higher in intermediate
EGFR-expressing cell lines than high
expressing cell line, the uptake was the lowest
in the low EGFR-expressing cell line. Possible
explanations for the mismatch may  include
inadequate vasculature and perfusion,
resulting in a heterogeneous and limited tracer
uptake.
EGFR  2010
[20]
86Y-CHX-A”-DTPA-
cetuximab
(3.8–4.0 MBq)
athymic nude mice
with subcutaneous
xenografts
LS-174T
HT29
PC-3
DU145
SKOV3
SHAW
1 to 3 days
%ID/cc
High EGFR expressing cell lines had the highest
tracer uptake, which could be blocked
dose-dependently by adding cold cetuximab.
EGFR  2010
[21]
64Cu-DOTA-
cetuximab
(7–8 MBq)
athymic nude mice
with subcutaneous
xenografts
UM-SCC-22B
SCC1
4 to 48 h
% ID/g
The highest tracer uptake was seen in the low
EGFR expressing tumor, which also seemed to
grow on cetuximab. This was ascribed to
decreased vessel density and vascular
permeability.
EGFR  2013
[22]
[89Zr]cetuximab
(step 1: 2 × 60MBq;
Step 2: 120 MBq)
9 patients (6 NSCLC
and 3 HNC) were
co-injected with
[89Zr]cetuximab
and cold cetuximab
prior to scanning; prim
objective was  safety,
secondary objective
was tumor imaging
Step 1: at days 4, 5, 6 p.i.
(patient 1 was also scanned
at day 12 p.i.)
Step 2: at days 5, 6, 7 p.i.
TBR
No toxicity was observed in both steps.
Heterogeneous uptake was seen in tumors.
Best timing for TBR may  be at late time points
(up to 12 days p.i.)
Please cite this article in press as: I. Bahce, et al., Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET,
Lung Cancer (2016), http://dx.doi.org/10.1016/j.lungcan.2016.05.025
ARTICLE IN PRESSG ModelLUNG-5125; No. of Pages 13
6  I. Bahce et al. / Lung Cancer xxx (2016) xxx–xxx
Table  2 (Continued)
Drug
target
Year
Ref
Tracer (injected
dose)
Design—scanned
population
Xenograft cell line Scanning protocol
–  Timinga
– uptake parameter
Resultsb
EGFR 2015
[23]
[89Zr]cetuximab
(37 ± 1 MBq)
10 KRASwt mCRC
patients were
co-injected with
[89Zr]cetuximab
and cold cetuximab
1 h to 10 days
SUV
Six patients had hotspots, 4 out of 6 had
clinical beneﬁt, while 3 out of 4 patients
without hotspots had progressive disease.
VEGF-A  2007
[24]
[89Zr]bevacizumab
(3.5 ± 0.5 MBq)
athymic nude mice
with subcutaneous
xenografts
SKOV-3 1 to 7 days
%ID/g
Increased tumor uptake was seen from 3 days
onward.
VEGF-A  2010
[25]
[89Zr]bevacizumab
(6 ± 0.27 MBq)
In xenografted athymic
nude mice, PET was
performed before and
after HSP90 inhibition
therapy (for 2 weeks)
A2780
CP70
At days 1 and 6 p.i.
%ID/g
The untreated high VEGF-A expressing tumor
showed high uptake, which decreased after
therapy together with VEGF expression, vessel
density, and proliferation rate.
VEGF-A  2011
[26]
[64Cu]bevacizumab
(5–8 MBq)
nude mice with
subcutaneous
xenografts
HT29 1 to 48 h
%ID/g
Tumor tracer uptake was increased, correlating
with tumor EGFR expression. Tracer uptake
was blocked by adding cold bevacizumab.
VEGF-A 2011
[27]
86Y-CHX-A′′-DTPA-
bevacizumab
(1.8–2.0 MBq)
athymic nude mice
with subcutaneous
xenografts
LS-174T
SKOV-3
MSTO-211H
1 to 3 days
%ID/cc
Tracer uptake was  highest in the 2 high VEGF
expressing tumors. Tracer uptake was blocked
by  adding cold bevacizumab.
VEGF-A 2012
[28]
64Cu-NOTA-
bevacizumab-
800CW (a dual
labeled
bevacizumab with
800CW (i.e. a NIRF
dye) and
64Cu-NOTA (i.e. a
PET label))
(5–10 MBq)
athymic nude mice
with subcutaneous
xenografts
U87MG 4 to 72 h
% ID/g
Tumor uptake was  visible, this was correlated
to ex vivo NIRF imaging. Uptake was blocked
by adding cold bevacizumab.
VEGF-A 2012
[29]
[89Zr]bevacizumab
(5 MBq)
In xenografted nude
mice, PET was
performed before and
at day 9 of everolimus
therapy (for 2 weeks)
A2780 At day 6 p.i.
SUVmean
Tracer uptake decreased with everolimus
therapy, correlating with decreased VEGF-A in
tumor lysates.
VEGF-A 2013
[30]
[64Cu]bevacizumab
(2.96–3.7 MBq)
athymic nude mice
with subcutaneous
xenografts underwent
PET before and after
everolimus therapy
(for 7 days)
786-O At 24 h p.i.
SUV
High tracer uptake was seen in the tumor,
which decreased with everolimus therapy
together with VEGF secretion, VEGFR
activation, and growth arrest.
VEGF-A 2013
[31]
[89Zr]bevacizumab
(37 MBq)
23 breast cancer
patients underwent a
PET scan prior to
surgery
At 4 days p.i.
SUVmax
Tracer uptake could be visualized in 25 out of
26 tumors and tracer uptake correlated with
tumor VEGF-A levels.
VEGF-A 2014
[32]
[89Zr]bevacizumab
(36.4 ± 0.9 MBq)
7 NSCLC patients were
scanned prior to
treatment with
bevacizumab
combined with
carboplatin-paclitaxel
At day 4 and 7 p.i.
SUVpeak
Tracer uptake of [89Zr]bevacizumab was visible
in all patients and showed a positive trend
between tracer uptake and PFS and OS.
VEGF-A 2014
[33]
[89Zr]bevacizumab
(37 MBq)
14 NET patients
underwent PET scans
at baseline and 2 and
12 weeks after start of
everolimus therapy
At day 4 p.i.
SUVmax and SUVmean
In 4 patients no uptake was seen. In 10
patients, 19% of tumor lesions above 1 cm were
visualized. SUVmax decreased by 7% at 2 weeks
and 35% at 12 weeks. Decrease during therapy
was correlated to RECIST response at 6 months.
VEGF-A  2015
[34]
[89Zr]bevacizumab
(37 MBq)
22 mRCC patients were
scanned at baseline
and 2 and 6 weeks
after start of therapy
using bevacizumab
with either IFN- or
sunitinib
At day 4 p.i.
SUVmax and SUVmean
Intrapatient and interpatient heterogeneity
was seen in tracer uptake. SUVmax decreased
at 2 and 6 weeks on bevacizumab/IFN-
therapy, however, with bevacizumab/sunitinib
a slight initial decrease at 2 weeks followed by
an increase was seen. Baseline SUVmax > 10
was associated with improved PFS. No
correlation was seen between SUVmax and
blood VEGF-A levels.
VEGFR-
2
2015
[35]
64Cu-NOTA-
ramucirumab
(5–10 MBq)
athymic nude mice
with subcutaneous
xenografts
HCC4006
A549
3 to 48 h
%ID/g
Uptake of 64Cu-NOTA-ramucirumab was
higher in VEGFR-2 positive tumors, uptake was
blocked by adding cold ramucirumab.
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Table  2 (Continued)
Drug target Year
Ref
Tracer (injected
dose)
Design—scanned
population
Xenograft cell line Scanning protocol
–  Timinga
– uptake parameter
Resultsb
PD1 2015
[36]
64Cu-DOTA-(anti-
mouse)PD1
(7–8 MBq)
xenografted nude
transgenic
Fox(p3 + ).LuciDTR4
mice, known to express
PD-1 on their CD4(+)
T-cells were scanned
B16-F10 1 to 48 h
%ID/g
High tracer uptake was seen in lymphoid
organs and tumors. BLI images of T-cells
conﬁrmed lymphocyte inﬁltration of tumors at
the time of PET imaging. Tracer uptake
decrease by adding unlabeled antibody.
Abbreviations: %ID/g = percentage injected dose per gram; HNC = head and neck cancer; KRASwt = KRAS (Kirsten rat sarcoma viral oncogene homolog) wild type;
mCRC  = metastatic colorectal cancer; mRCC = metastasized renal cell carcinoma; NIRF = near-infrared ﬂuorescence; NSCLC = non-small cell lung cancer; p.i. = post injection;
RECIST  = response evaluation criteria in solid tumors [37]; SUV = standardized uptake value; SUVmax = maximum SUV; SUVmean = average SUV per volume of interest; SUV-
peak  = average SUV within a 1cc sphere around the maximum SUV.
Cell lines: Colorectal adenocarcinoma (LS-174T, HT29, HCT-8, HCT-116, and SW620); Murine colorectal carcinoma (CT-26); Melanoma (A375, B16-F10); Breast cancer (BT-
474,  MDA-MB-231, MDA-MB-468, MDA-MB-435, and T-47D); Head and neck squamous cell carcinoma (SQB20, SAS, UM-SCC-22B, and SCC1); Prostate cancer (PC-3, DU145);
Epidermoid cancer (A431); Malignant mesothelioma (NCI-H226, NCI-H2052, and MSTO-211H); Ovarian cancer (SKOV3, A2780, and CP70); Pancreatic cancer (SHAW);
Glioblastoma (U-373 MG, U87MG); Cervical cancer (CaSki); Renal cell carcinoma (786-O); NSCLC (HCC4006, A549).
a Time interval from injection to scanning.
b Tracer uptake refers to tumor tracer uptake, unless stated otherwise.
Table 3
Typical differences between immuno-PET and TKI-PET.
Immuno-PET TKI-PET
Parent molecule mAbs TKIs
Scanning protocol Static Static Dynamic
Radionuclide (Decay
half-life)
• Copper-64 (12,7 h)
• Yttrium-86 (14,7 h)
•  Bromine-76 (16,1 h)
•  Zirconium-89 (78,4 h)
• Iodine-124 (4,2 days)
• Carbon-11 (20,4 min)
• Fluorine-18 (109,8 min)
Scanning parameters
• Injection to scanning
time interval
• Uptake parameters
• up to several days
• simpliﬁed parameters:
SUV (and its variants
such as SUVmax and
SUVpeak), TBR, TRR, etc.
• up to several hours
• simpliﬁed parameters:
SUV and variants, TBR,
TRR, etc.
• up to several hours
• dynamic: K1, Ki, VT, etc.
Advantages • whole body scans
• highly speciﬁc parent
molecules
• stable inert labeling
•  easy to process uptake
parameters
• shippable for
widespread use
• whole body scans
• easy to process uptake
parameters
• shippable for
widespread use
• PK modeling
•  highly accurate uptake
parameters
Limitations/caveats • radiation burden • accuracy of uptake
parameters may  be low
depending on the PK
modeling of the tracer
• no whole body scans
possible
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UVmax = maximum SUV; SUVpeak = average SUV within a 1 mL  sphere located a
nhibitors; TRR = target-to-reference tissue ratio; VT = volume of distribution.
n mice xenografted with VEGF-A expressing tumors as compared
o non-VEGF expressing tumors [24,27,28]. Moreover, Chang et al.
lso showed that tumor uptake of [64Cu]bevacizumab decreased
fter everolimus therapy, together with a decrease in VEGF-A secre-
ion, VEGFR inactivity and growth arrest [30]. Similarly, tumor
89Zr]bevacizumab uptake decreased after treatment with a HSP90
nhibitor, known to decrease VEGF-A expression [25]. Tumor tracer
ptake was blocked by adding nonlabeled bevacizumab, support-
ng the notion that there is speciﬁc binding. These ﬁndings indicate
89Please cite this article in press as: I. Bahce, et al., Personalizing NSCLC t
Lung Cancer (2016), http://dx.doi.org/10.1016/j.lungcan.2016.05.025
hat uptake [ Zr]bevacizumab is correlated with varying levels
f VEGF-A expression. This is very interesting, as VEGF-A is typ-
cally considered to be a soluble ligand. Possibly, tumor uptake
ay  be caused by high paracrine expression and subsequent bind-noclonal antibodies; PK = pharmacokinetic; SUV = standardized uptake value;
 the pixel with maximum SUV; TBR = tumor-to-blood ratio; TKIs = tyrosine kinase
ing to extracellular matrix glycoproteins that act as non-signaling
co-receptors, facilitating the binding of VEGF to VEGFR molecules
[40]. To date, clinical PET studies using [89Zr]bevacizumab were
performed in patients with breast cancer, neuro-endocrine tumors
(NET), renal cell carcinoma, and NSCLC. The concept of imaging the
tumor VEGF-A expression using [89Zr]bevacizumab was investi-
gated in breast cancer patients by Gaykema et al. [31]. They showed
that in 25 out of 26 tumors tracer uptake could be visualized,
and that uptake was  correlated to the tumor VEGF-A expres-herapy by characterizing tumors using TKI-PET and immuno-PET,
sion levels. Bahce et al. scanned 7 advanced NSCLC patients using
[89Zr]bevacizumab prior to treatment with bevacizumab combined
with carboplatin and paclitaxel [32]. Using PET, tumors could be
visualized in all patients (see Fig. 4). Tracer uptake showed het-
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Fig. 4. Axial (A) and coronal (B) CT-fused [18F]afatinib PET images are shown of a NSCLC patient, harboring an EGFR exon 19 deletion. Increased activity is seen in the rims of
the  tumor (T), located in the right upper lobe. The central photopenic area correlates with central tumor necrosis as seen on the FDG images (C). Also, the liver (L) and urinary
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18F]afatinib PET images were obtained at 90 min  post injection of 75 MBq [18F]afat
rogeneity of uptake within tumor lesions and between lesions
ithin the same patient. The level of tracer uptake was  associated
ith improved progression free survival (PFS) and overall survival
OS). Comparable ﬁndings were done using this tracer in patients
enal cell carcinoma and NET treated with bevacizumab/IFN-a
nd everolimus, showing association of high baseline uptake with
onger PFS and early change in uptake with tumor response, respec-
ively [33,34].
In mice with VEGFR-2 positive xenografts, [64Cu]ramucirumab
howed higher uptake as compared to target-negative xenografts.
lso, tumor uptake was blocked by adding cold ramucirumab, again
ndicative of speciﬁc binding.
.3. Immune checkpoint inhibitors
Many cancers, including NSCLC, inhibit anti-tumor immune
esponses via the programmed death-1 (PD-1) pathway [41].
SCLC patients treated with anti-PD-1 antibodies achieve tumor
esponses in approximately 20%. The presence of tumor inﬁltrat-
ng lymphocytes that express PD-1 may  be predictive for response
o anti-PD-1 therapy. Natarajan et al. used a radiolabeled anti-PD1
ntibody, i.e. [64Cu]-DOTA-(anti-mouse)PD1, in mice that express
D-1 on their T-cells [36]. These mice were xenografted with
elanoma cells. High tracer uptake was seen in lymphoid organs
nd tumors. At the time of PET imaging, lymphocyte inﬁltration of
umors could be demonstrated by bioluminescence imaging. Also,
y adding nonlabeled antibody the tumor tracer uptake decreased.
hese ﬁndings support the notion that PD-1 target expression can
e imaged using immuno-PET. No published preclinical studies
sing anti-PDL-1 or anti-CTLA4 antibodies could be found. Also,
o the best of our knowledge, no clinical studies using anti-PD1
ntibodies have been reported yet.
.4. Clinical implication of immuno-PET in NSCLC
Preclinical immuno-PET studies have been performed using
adiolabeled mAbs directed against nearly all currently actionable
Ab  targets in NSCLC, i.e. EGFR, VEGF-A, VEGFR2 and PD-1. These
tudies have consistently shown that immuno-PET has the capac-
ty for imaging target expression. However, only a very limited
umber of clinical studies have been published using radiolabeledPlease cite this article in press as: I. Bahce, et al., Personalizing NSCLC t
Lung Cancer (2016), http://dx.doi.org/10.1016/j.lungcan.2016.05.025
Abs that are of interest in the treatment of NSCLC. These pilot
tudies, all used [89Zr]bevacizumab, and demonstrated that tumor
ptake could be visualized and to a certain extent quantiﬁed. They
lso aimed to generate hypotheses about the predictive value oflites. The color code indicates the radioactivity concentration (Bq/mL). These static
nd were part of a series of whole body scans, performed for dosimetric purposes.
tumor tracer uptake. Although, different interesting correlations
were found between tumor [89Zr]bevacizumab uptake and clini-
cal outcome, the predictive or prognostic value of imaging tumor
VEGF-A with immuno-PET is still unclear. Larger trials are needed
to evaluate whether [89Zr]bevacizumab uptake is able to identify
patients that will beneﬁt from bevacizumab therapy.
More than a tool for research, immuno-PET imaging is poten-
tially a future standard clinical assessment tool. Its many practical
advantages, such as easy to produce stable and shippable trac-
ers, and the possibility for whole body scanning protocols using
simpliﬁed parameters for easy uptake measurement, will facilitate
a broad application. However, its clinical success will depend on
how tracer uptake will relate to target expression and will pre-
dict for therapy efﬁcacy of the antibody that will be chosen as
a tracer. This seems very promising for cancer immunotherapy.
For example, the expression levels of PD1 and PD-L1 on tumor
inﬁltrating T-cells or tumor cells, although not exclusionary, are
indicative of an improved immunotherapy outcome in patients
with non-squamous NSCLC. The use of the current pathology-
based PD1 and PD-L1 expression markers, however, is hampered
by unresolved issues such as varying immunohistochemistry anti-
bodies, tissue preparation and processing variabilities, PD1/PD-L1
differences between primary versus metastatic biopsies, oncogenic
versus induced PD-L1 expression levels that changes over time, and
staining of tumor versus immune cells [41]. Immuno-PET could be
used to overcome these limitations, as it provides a noninvasive
means for repeated whole-body scanning, and to guide treatment
decision management.
4. TKI-PET
In NSCLC, TKIs frequently target EGFR (10% of non-squamous
NSCLC in Western population), ALK (5%), BRAF (2%), ROS1 (1–2%),
RET (1–2%) and MET  (2–4%) (see Fig. 3) [42]. The main differ-
ences between TKI-PET and immuno-PET are shown in Table 3.
Typically, TKIs are small molecules with a rapid PK proﬁle that
inhibit the kinase activity of various proliferation pathways. Tumor
TKI accumulation depends not only on the presence of targeted
kinase molecules, but also on their afﬁnity. TKIs compete with ATP
molecules for binding to the tyrosine kinase target. For example,
erlotinib competes with ATP for the EGFR kinase domain. A 137-herapy by characterizing tumors using TKI-PET and immuno-PET,
fold higher binding rate of erlotinib relative to ATP was seen in ex
vivo tumors with EGFR exon 19 deletions, however, the presence of
a secondary T790 M mutation in EGFR exon 20 increased the afﬁnity
to ATP while decreasing for erlotinib [43]. Alterations in TKI afﬁnity,
Please cite this article in press as: I. Bahce, et al., Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET,
Lung Cancer (2016), http://dx.doi.org/10.1016/j.lungcan.2016.05.025
ARTICLE IN PRESSG ModelLUNG-5125; No. of Pages 13
I. Bahce et al. / Lung Cancer xxx (2016) xxx–xxx 9
Table  4
TKI-PET trials.
Drug target Year Ref. Tracer (injected dose) Design—scanned
population
Xenograft cell line Scanning protocol
–  Timinga
– Uptake parameter
Resultsb
EGFR 2007
[44]
[11C]PD153035
(2.6 ± 0.7 MBq)
No PET scans were
performed, only
biodistribution analysis
was performed in nude
mice with subcutaneous
xenografts
MDA-MB-468
A549
MDA-MB-231
Biodistribution
measurements at 10, 30,
and 60 min p.i.
%ID/g
Higher tracer uptake was
seen in high EGFR
expressing tumors. Tracer
uptake was blocked by cold
PD153035.
EGFR  2011
[45]
[11C]PD153035
(280.3 ± 113.6 MBq)
21 NSCLC patients (all
histologies, EGFR
mutational status
unknown) underwent 3
PET scans (at baseline and
1  and 6 weeks after start of
erlotinib therapy).
4 min at 20 min p.i.
SUVmax
Tracer uptake showed a
good correlation with OS
and PFS on erlotinib
therapy.
EGFR  2015
[46]
[11C]PD153035
(? MBq)
nude mice with
subcutaneous xenografts
HCC827
PC9
A549
H1975
30 min
SUV and T/N
Sensitive cell lines showed
higher tracer uptake and
positive correlation with
in vitro pEGFR expression.
EGFR  2013
[47]
[124I]morpholino-IPQA
(2.6 MBq)
NOD/SCID mice with
subcutaneous xenografts
were scanned before and
1  h after cold geﬁtinib.
H1299 cell lines
transfected with
L858R, E746-A750del,
and wild type EGFR
60 min at 0 min p.i. and
30 min at 24 h p.i.
%ID/g
Higher tracer uptake was
seen in sensitive tumors.
Tracer uptake decreased
after pretreatment with
geﬁtinib.
EGFR  2011
[48]
[18F]F-PEG6-IPQA
(7.4 MBq)
nude mice with
subcutaneous xenografts
H3255
H441
PC 14
H1975
2 h dynamic scanning at
0 min  p.i., followed by
static scan at 3 h p.i.
%ID/g and T/M
Tracer uptake was
correlated to EGFR
mutational status, the
highest uptake was
demonstrated in L858 R
harboring tumors.
EGFR  2008
[49]
[18F]geﬁtinib
(7.4–18.5 MBq)
xenografted SCID mice
were used for [18F]geﬁtinib
PET scans and vervet
monkeys for
biodistribution analyses
U87
U87-EGFR
H3255
H1975
2 h at 0 min p.i.
SUV
No difference was seen in
tracer uptake between
tumors, due to high
nonspeciﬁc uptake of
[18F]geﬁtinib.
EGFR  2009
[50]
[11C]erlotinib
(10 − 15 MBq)
nude mice with
subcutaneous xenografts
A549
NCI358
HCC827
90 min at 0 min p.i.
Bq/cc TAC
Tracer uptake was  higher
uptake in the sensitive cell
line.
EGFR  2011
[51]
[11C]erlotinib
(500 ± 50 MBq)
13 NSCLC patients (all
histologies, EGFR
mutational status
unknown) were scanned
(using FDG and
[11C]erlotinib) prior to
erlotinib therapy and after
12 weeks (with FDG only)
90 min at 0 min p.i.
Hotspots (i.e.
tumor-to-background
ratio)
Tracer uptake was
associated with better
clinical outcome to
erlotinib therapy. Four out
of 9 patients showed
increased tracer uptake,
amongst which 1 died prior
to response evaluation and
3 responded to erlotinib
therapy. Nine out of 13
patients had no tracer
accumulation, of which 3
died prior to response
evaluation, 2 had a stable
disease, and 4 had
progressive disease on
erlotinib therapy.
EGFR  2011
[52]
[11C]erlotinib
(433 MBq)
1 NSCLC patient with an
EGFR exon 19del and brain
metastases was scanned
prior to ﬁrst line erlotinib
therapy
60 min at 0 min p.i.
tumor-to-cortex ratio
Brain metastases showed
high tracer uptake and a
radiologic response to
erlotinib therapy.
EGFR  2013
[53]
[11C]erlotinib
(0.16 ± 0.12 mCi)
athymic nude mice with
subcutaneous xenografts
PC9
HCC827
U87
U87-EGFR
SW620
2 h at 0 min p.i.
SUV
Higher tracer uptake was
seen in sensitive tumors,
uptake was blocked by
adding cold erlotinib.
EGFR  2013
[54]
[11C]erlotinib
(256 ± 53 MBq)
10 NSCLC patients (5
EGFRmut vs. 5 EGFRwt)
underwent a [15O]H2O PET
scan followed by 2
[11C]erlotinib scans (as test
and retest)
60 min at 0 min p.i.
VT
Tracer uptake showed
good test retest
repeatability. Also, higher
uptake was seen in
EGFRmut patients, which
was  independent of blood
perfusion as measured by
[15O]H2O inﬂux.
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Table  4 (Continued)
Drug target Year Ref. Tracer (injected dose) Design—scanned
population
Xenograft cell line Scanning protocol
–  Timinga
– Uptake parameter
Resultsb
EGFR 2015
[55]
[11C]erlotinib
(16.4 ± 0.6 MBq)
athymic nude mice with
subcutaneous xenografts
HCC827
QG56
H3255
H1975
60 min  at 0 min p.i.
SUV
Tracer uptake was higher
in sensitive cell lines,
namely EGFR exon 19del
had the highest uptake.
EGFR  2016
[56]
[11C]erlotinib
(349 ± 46 MBq)
10 patients (EGFRmut)
underwent a [15O]H2O
followed by a [11C]erlotinib
scan, both on and off
erlotinib therapy
60 min  at 0 min p.i
VT and TBR
Tracer uptake was
decreased in all patients
during erlotinib therapy,
supporting the notion that
[11C]erlotinib exhibits
speciﬁc binding in tumors,
while tumor perfusion did
not change.
EGFR,
ERBB2
2015
[57]
[11C]erlotinib
(8–10 MBq)
[18F]afatinib
(4–6 MBq)
athymic nude mice with
subcutaneous xenografts
HCC827
A549
H1975
[11C]erlotinib: 90 min  at
0  min  p.i.
[18F]afatinib: 120 min at
0 min  p.i.
%ID/g and
tumor-to-background ratio
Both tracers showed higher
uptake in the sensitive
tumors. [18F]afatinib
demonstrated better tumor
retention in all xenograft
models.
Abbreviations:  %ID/g = percentage injected dose per gram; Bq/cc TAC = activity as determined by becquerels per volume of interest plotted in a time activity curve;
EGFRmut = activating EGFR mutations; EGFRwt = wild type EGFR; p.i. = post injection; SUV = standardized uptake value; TBR = tumor-to-blood ratio; T/N = tumor tissue vs.
non-tumor tissue uptake ratios; T/M = tumor to muscle ratio; VT = volume of distribution
Cell  lines: NSCLC, EGFR exon 19 deletion (HCC827, PC9), EGFR exon 21 L858 R (H3255), EGFR dual mutations L858R/T790 M (H1975), EGFR wild type (A549 (moderate EGFR
expression), QG56, NCI358, H441, and PC14); Breast cancer, EGFR wild type (MDA-MB-468 (high EGFR expression), MDA-MB-231 (low EGFR expression)); Glioblastoma, EGFR
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.e. the TKI/ATP-binding ratio, are critical in TKI therapy efﬁcacy. For
KI-PET, adequate imaging of the changes in TKI afﬁnity may  play
he most crucial role in successfully predicting therapy response.
Contrary to mAbs, TKIs are typically labeled with carbon-11
r ﬂuorine-18, as the relatively short activity half-life of these
adionuclides are best ﬁtting with the biological half life of TKIs
see Tables 1 and 4). Furthermore, TKI molecules usually have car-
on and sometimes ﬂuorine atoms that can be substituted with
arbon-11 and ﬂuorine-18 atoms, whereby their molecular conﬁg-
ration and PK characteristics can remain identical. After injection,
adiolabeled TKIs are rapidly bound to their targets, and in case
f reversible binders also rapidly released from their targets. Usu-
lly, TKIs undergo rapid renal or biliary clearance. In this setting,
ynamic scanning is best used for pharmacokinetic modeling and
uantitative tracer uptake analysis (see Fig. 2). Although the anal-
sis of a dynamic scan is more laborious than a static scan, the high
ccuracy of its results is clearly an advantage. Another advantage
f using short-lived radionuclides is the short time period of decay,
ausing less radiation burden and patients can undergo a second
ET scan relatively soon after the ﬁrst one, in case of carbon-11
hey can even undergo it on the same day.
.1. EGFR TKI (not in clinical use)
[11C]PD153035, i.e. 11C-labeled 4-N-(3-bromoanilino)-6,7-
imethoxyquinazoline, is a PET tracer that is based on a reversible
GFR TKI. In xenografted mice, [11C]PD153035 showed higher
ptake in EGFR TKI sensitive NSCLC tumors as compared to
nsensitive tumors [44,46]. Also, the uptake correlated positively
ith the level of EGFR expression, however, this was  only seen
n the sensitive tumors. When unlabeled PD153035 was added
rior to tracer infusion, the uptake of [11C]PD153035 in tumors
as blocked, indicating that there was speciﬁc binding. Meng et al.Please cite this article in press as: I. Bahce, et al., Personalizing NSCLC t
Lung Cancer (2016), http://dx.doi.org/10.1016/j.lungcan.2016.05.025
tudied the potential of this tracer for predicting clinical outcome
f erlotinib therapy in 21 advanced NSCLC patients (EGFR status
nknown) who had disease progression after chemotherapy [45].
he study showed that enhanced [11C]PD153035 tumor uptake,xpress EGFR)); Colon cancer, EGFR wild type (SW620 (very low EGFR expression)).
as measured using SUVmax prior to or within 1–2 weeks after
start of erlotinib treatment, correlated strongly with a better OS
and longer PFS (HR = 0.40, P = 0.002, and HR = 0.044, P, 0.001, resp).
Patients with high SUVmax (≥median) survived more than twice
as long as patients with a low SUVmax (median OS = 11.4 vs. 4.6
mo,  P = 0.002; PFS = 4.4 vs. 1.8 mo,  P < 0.001). The authors also
reported that this correlation was  independent of histology. They
proposed that this could be an added value of [11C]PD153035, as
EGFR-activating mutations are uncommon in squamous carcinoma
NSCLC tumors.
Unlike [11C]PD153035, many 4-anilinoquinazoline derivatives
that were proposed as EGFR imaging tracers showed inferior
in vivo stability, high non-speciﬁc binding and rapid dissocia-
tion rates. To deal with the latter problem irreversible EGFR
TKIs, such as [124I]morpholino-IPQA and [18F]F-PEG6-IPQA [47,58],
were developed. These tracers showed higher accumulation in
EGFR mutated NSCLC tumors than in EGFR wild type tumors.
[18F]F-PEG6-IPQA demonstrated superior PK characteristics, such
as better water solubility, renal clearance, and lower background
noise than [124I]morpholino-IPQA. Moreover, the main metabolite
of [18F]F-PEG6-IPQA, i.e. [18F]F-PEG6, was  unable to cross cell mem-
branes, indicating that the measured tumor activity originated from
the parent tracer. A clinical trial using [18F]F-PEG6-IPQA is now
ongoing (NCT01320059).
4.2. Geﬁtinib
The potential use of [18F]geﬁtinib as a PET tracer for predict-
ing EGFR expression and mutational status in NSCLC xenografts
was assessed by Su et al. [49]. No difference was seen in uptake of
[18F]geﬁtinib in xenografts with low and high EGFR expression, andherapy by characterizing tumors using TKI-PET and immuno-PET,
no difference was  seen between sensitive and resistant cell lines.
These ﬁndings were ascribed to a high degree of non-speciﬁc bind-
ing, resulting from geﬁtinib’s high lipophilicity. Besides ﬂuorine-18,
the synthesis of carbon-11 labeled geﬁtinib has also been published
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Fig. 5. Axial CT-fused PET images in a NSCLC patient are shown, obtained after 5 (A) and 7 (B) days post injection (p.i.) of 37MBq [89Zr]bevacizumab. Increased tracer
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he  activity ratio in the blood pool is much lower than in the tumor, improving the 
58]. However, to our best knowledge, no clinical or preclinical
tudies of [11C]geﬁtinib in NSCLC have been reported.
.3. Erlotinib
Erlotinib labeled with carbon-11, i.e. [11C]erlotinib, was  used
n several preclinical studies in mice, xenografted with NSCLC
umors [50,53,55,57]. All studies reported increased uptake of
11C]erlotinib in sensitive tumors. Also, by adding nonlabeled
rlotinib, the uptake was blocked, indicating this tracer’s speciﬁc
inding capacity. The ﬁrst clinical study using [11C]erlotinib, by
emon et al., investigated 13 NSCLC patients that were planned
o receive erlotinib therapy [51]. A [11C]erlotinib PET was  per-
ormed prior to erlotinib therapy, patients also underwent an
DG PET scan prior to therapy and 12 weeks after start of ther-
py. EGFR mutational status was not evaluated. In 4 patients, the
11C]erlotinib scan showed increased uptake in tumors and malig-
ant lymph nodes. Out of these 4 patients, 3 showed a stable disease
o erlotinib therapy, the remaining patient died before evalua-
ion. Out of the remaining 9 patients without increased uptake, 3
ied before evaluation, 2 had a stable disease, and 4 patients had
isease progression at 12 weeks. The authors also reported that
n some cases [11C]erlotinib PET could identify lesions that had
ot been visualized using FDG PET, however, these lesions were
ot conﬁrmed by pathology. The same investigators published a
ase report of a NSCLC patient with an activating EGFR exon 19
eletion and brain metastases [52]. The [11C]erlotinib PET showed
ccumulation in the brain metastases. Post-treatment MRI  and CT
emonstrated regression of both the brain metastases and primary
ung tumor. Next, Bahce et al. performed a quantitative study using
 dynamic scanning protocol with continuous arterial sampling
n 10 NSCLC patients [54]. Full tracer pharmacokinetic analysis
etermined that the 2-tissue reversible compartment model using
olume of distribution (VT) as uptake parameter ﬁtted the PET
ata best. By using VT, tracer uptake could be assessed more accu-
ately than by SUV. This study demonstrated that [11C]erlotinib VT
as higher in patients with an activating EGFR exon 19 deletion
han in patients with wild type EGFR tumors. This difference was
tatistically signiﬁcant and was not determined by differences in
GFR expression levels or tumor perfusion, which was assessed
y quantitative PET studies using radiolabeled water ([15O]H2O).
n a follow up clinical study, 10 patients were scanned on and offPlease cite this article in press as: I. Bahce, et al., Personalizing NSCLC t
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rlotinib therapy [56]. Tumor tracer uptake decreased in all patients
uring erlotinib therapy, supporting the notion that [11C]erlotinib
xhibits speciﬁc binding, while tumor perfusion as measured by
15O]H2O remained unchanged during therapy. In addition, Yaqubt lower lobe. The central photopenic area correlates with central tumor necrosis as
e blood pool, i.e. heart (H), as in the peripheral tumor parts. However, at day 7 p.i.
 uptake signal. The color code indicates the radioactivity concentration (Bq/mL).
et al. showed that the simpliﬁed uptake parameter that best rep-
resented tumor [11C]erlotinib uptake was  TBR in the postinjection
interval between 40 and 60 min. TBR was more accurate than SUV,
however, was less accurate than VT [59]. A clinical trials using this
tracer is ongoing (Dutch trial register NTR3670).
4.4. Afatinib
Another EGFR TKI that is approved for the treatment of EGFR
mutated NSCLC is afatinib, which is a second generation irre-
versible EGFR TKI. In contrast to geﬁtinib and erlotinib that inhibit
only EGFR, afatinib inhibits EGFR as well as ERBB2 and ERBB4.
Afatinib has been radiolabeled with ﬂuorine-18, i.e. [18F]afatinib.
The ﬁrst preclinical study was performed by Slobbe et al. using
xenografted mice [57]. Tumors with activating EGFR showed a
higher [18F]afatinib uptake as compared to wild type EGFR tumors.
Adding nonlabeled afatinib blocked tumor [18F]afatinib uptake.
Analysis of [18F]afatinib metabolism and biodistribution in tumor-
bearing mice demonstrated high stability of the tracer in plasma
(>80% of intact [18F]afatinib at 45 min  p.i.), rapid clearance from
both blood and muscle tissue and rapid tumor accumulation (after
10 min  p.i.). Tumor retention of [18F]afatinib was shown to be
relatively stable from 5 min  until 120 min post injection. When
compared to [11C]erlotinib, higher tumor-to-background ratios
were seen with [18F]afatinib in EGFR wild type and EGFR exon 19del
(1.0 vs. 1.5 and 1.9 vs. 2.3, respectively) tumors, no difference was
seen in tumors harboring a T790 M secondary mutation. A clinical
trial using [18F]afatinib is ongoing at our center (Dutch trial register
NTR5203) (see Fig. 5).
4.5. Clinical implications of TKI-PET in NSCLC
To our best knowledge, only EGFR TKI were used in the pub-
lished TKI-PET studies in NSCLC. [11C]PD153035 and [11C]erlotinib
were studied the most and have consistently demonstrated to
achieve higher uptake in tumors with activating EGFR mutations,
indicating that TKI-PET can image increased EGFR afﬁnity to TKI.
In clinical pilot studies, not only tumor uptake of both tracers
could be visualized, signiﬁcant correlations were found between
high tracer uptake and better erlotinib therapy outcome. How-
ever, these tracers are not suitable for widespread clinical use due
to the short half-life of their carbon-11 label. To circumvent thisherapy by characterizing tumors using TKI-PET and immuno-PET,
limitation, ﬂuorine-18 labeled next generation irreversible EGFR
TKI, e.g.[18F]F-PEG6-IPQA and [18F]afatinib, were studied. These
tracers are expected to be better suited for clinical use as the
ﬂuorine-18 label allows for their shipment to other PET centers.
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oreover, in preclinical studies, these tracers did show better
umor-to-background ratios as compared to [11C]PD153035 and
11C]erlotinib, respectively. However, these next generation trac-
rs are expected to bind irreversibly, meaning that the uptake of
hese tracers will be strongly dependent on the delivery to the tar-
et receptor, i.e. on tumor perfusion, which may  impede correct
uantiﬁcation of uptake.
Overall, TKI-PET is a great research tool for pharmacokinetic
tudies, however, for TKI-PET tracers to become a standard clini-
al assessment tool across numerous countries and hospitals, some
ractical conveniences should be provided, for example the abil-
ty for assessing all tumor lesions by whole body imaging and the
se of stable and shippable tracers. TKI-PET tracers, fulﬁlling these
onditions are potentially applicable in the routine clinical practice
ecause this technique has the unique ability to image the afﬁn-
ty and therefore the sensitivity of a receptor for the studied TKI.
his was already demonstrated for EGFR, but besides EGFR, future
KI-PET studies should investigate TKIs directed against ALK, BRAF,
OS1, RET, and MET. For example, crizotinib, a multi-target TKI
sed in the treatment of ALK rearranged NSCLC, has also activity
gainst ROS1 and MET. Theoretically, in these patients, radiola-
eled crizotinib and PET may  predict therapy response irrespective
f the sensitizing DNA aberration that was found in the tumor. This
ould lead to a whole new way of personalizing therapy without
ecessarily performing tumor molecular analysis.
. In summary
In the last decade, the number of mAbs and TKI used in the treat-
ent of NSCLC rapidly increased as a result of the identiﬁcation of
ver more critical tumor targets. PET using radiolabeled targeting
Abs and TKIs can provide an imaging biomarker for personalizing
herapy.
In this review, we discussed that preclinical immuno-PET and
KI-PET studies have consistently shown their capacity for imaging
arget expression. At present, the results obtained in clinical stud-
es, mostly designed as pilot studies, suggest promising correlations
etween tumor tracer uptake and clinical outcome, although
ot conclusive and needing validation by future larger studies.
onetheless, taking into account their pioneering work and the
omplexity of the experimental setting in which they are per-
ormed, these studies pave the way towards better understanding
he mechanisms behind imaging targeted drugs and their potential
o predict tumor sensitivity to therapy.
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